New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

posted on Mar 02, 2017 10:51AM

"BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1"

Open Access DOI: http://dx.doi.org/10.1016/j.celrep.2017.02.011

https://www.ncbi.nlm.nih.gov/pubmed/28249162

http://www.cell.com/cell-reports/fulltext/S2211-1247(17)30176-6

Concise little write up on the study and its implications

"Combination of ground-breaking treatments offer powerful new path for blood cancer therapies"

https://medicalxpress.com/news/2017-03-combination-ground-breaking-treatments-powerful-path.html

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply